Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Different immunosuppressive drugs used in transplantation may reduce the body's defences
against infection differently. It is known that patients with Hepatitis C virus, known as
HCV, who switched from azathioprine to mycophenolate mofetil experienced an increase in viral
load. Despite this, mycophenolate mofetil is used because it prevents rejection more reliably
than azathioprine. Sirolimus is an another immunosuppressive agent that reliably prevents
rejection and may have antiviral activity. This study is designed to see if the viral load of
HCV and other viruses is reduced by switching from mycophenolate to sirolimus.